Combination Antifungal Therapy for Invasive Aspergillosis: Utilizing New Targeting Strategies

Steinbach, William J.
September 2005
Current Drug Targets - Infectious Disorders;Sep2005, Vol. 5 Issue 3, p203
Academic Journal
The optimal therapy for invasive aspergillosis (IA) is unknown, and there is little agreement on the exact antifungal management of IA. The previously stagnant landscape of antifungal choices for IA is rapidly changing with newer antifungals and newer targets. While amphotericin B has historically been the preferred therapy, recent studies support voriconazole as primary therapy or caspofungin as salvage therapy. However, even these newer therapies have only elevated clinical response rates to approximately 50%. Recent in vitro studies, animal models, and limited clinical reports suggest that combination antifungal therapy utilizing novel targeting strategies might offer improved outcome. Until very recently, combination antifungal therapy for IA was of little consequence since there were a limited number of possible permutations available. There has been a great deal of new data published exploring the possibilities of combination therapy, but clinicians need to be aware of the potential advantages and disadvantages of combination antifungal therapy for IA.


Related Articles

  • High rate of breakthrough invasive aspergillosis among patients receiving caspofungin for persistent fever and neutropenia. Lafaurie, M.; Lapalu, J.; Raffoux, E. // Journal of Invasive Fungal Infections;2010, Vol. 4 Issue 4, p150 

    In this study, the authors sought to determine the efficacy of antifungal agents for preventing breakthrough invasive aspergillosis (IA) in a cohort of patients with persistent fever and neutropenia who received empirical antifungal therapy. Caspofungin was the most prescribed antifungal agent,...

  • Antifungal Combination Therapy: Clinical Potential. Baddley, John W.; Pappas, Peter G. // Drugs;2005, Vol. 65 Issue 11, p1461 

    Combination antifungal therapy has been an area of research and clinical interest since systemic antifungals became available decades ago. In vitro and clinical data were generated for some of the more common invasive fungal infections, especially candidiasis, but until very recently few...

  • Antimicóticos de uso sistémico: ¿Con que opciones terapéuticas contamos? G., ANA MARÍA RIVAS; CARDONA-CASTRO, NORA // CES Medicina;2009, Vol. 23 Issue 1, p61 

    The prevalence of invasive fungal infections has increased over the past three decades owing to the increasing numbers of immunocompromised hosts. For many years, amphotericin B and flucytosine were the only available antifungal agents for invasive fungal infections. Fortunately, the antifungal...

  • Aspergillosis in the CLEAR outcomes trial: working toward a real-world clinical perspective. Kleinberg, M. // Medical Mycology;Feb2005 Supplement 1, Vol. 43, p289 

    Aspergillosis is a potentially lethal infection of immunocompromised patients. Until 10 years ago, antifungal therapy was largely limited to amphotericin B deoxycholate. Perceived poor response rates and inherent toxicities with amphotericin B deoxycholate were a major stimulus for the...

  • Current Developments in Anti-Fungal Agents. Carrillo-Mu�oz, A. J.; Quind�s, G.; Lopez-Ribot, J. L. // Current Medicinal Chemistry - Anti-Infective Agents;Dec2004, Vol. 3 Issue 4, p297 

    Invasive mycoses are important causes of morbidity and mortality among neutropenic and other immunocompromised patients. Candidiasis and aspergillosis are the most frequent mycoses but many other opportunistic fungal infections are emerging. The lack of appropriate diagnostic tools for an early...

  • Systematic review and meta-analysis of antifungal agents for preventing fungal infections in liver transplant recipients. Playford, E. G.; Webster, A. C.; Sorrell, T. C.; Craig, J. C. // European Journal of Clinical Microbiology & Infectious Diseases;Sep2006, Vol. 25 Issue 9, p549 

    A systematic review and meta-analysis was performed to evaluate the benefits and harms of antifungal prophylaxis in liver transplant recipients. Ten randomised trials comparing any prophylactic antifungal regimen with no antifungal agent or with another antifungal regimen were identified from...

  • Quantitative and Qualitative Analysis of the Antifungal Activity of Allicin Alone and in Combination with Antifungal Drugs. Young-Sun Kim; Kyung Sook Kim; Ihn Han; Mi-Hyun Kim; Min Hyung Jung; Hun-Kuk Park // PLoS ONE;Jun2012, Vol. 7 Issue 6, p1 

    The antifungal activity of allicin and its synergistic effects with the antifungal agents flucytosine and amphotericin B (AmB) were investigated in Candida albicans (C. albicans). C. albicans was treated with different conditions of compounds alone and in combination (allicin, AmB, flucytosine,...

  • Systematic review and meta-analysis of the tolerability and hepatotoxicity of antifungals in empirical and definitive therapy for invasive fungal infection. Wang, J. L.; Chang, C. H.; Young-Xu, Y. // Journal of Invasive Fungal Infections;2010, Vol. 4 Issue 4, p152 

    In this meta-analysis, the authors evaluated the hepatotoxicity of antifungal agents in the treatment of invasive fungal infections, and examined whether hepatotoxicity was the cause of treatment discontinuation and study withdrawal. The risk of hepatotoxicity was higher in patients with...

  • Adverse effects of antifungal therapies in invasive fungal infections: review and meta-analysis. Girois, S. B.; Chapuis, F.; Decullier, E.; Revol, B. G. P. // European Journal of Clinical Microbiology & Infectious Diseases;Feb2006, Vol. 25 Issue 2, p138 

    Amphotericin B is the main therapeutic agent for the treatment of invasive fungal infections; however, it is associated with significant toxicities that limit its use. Other systemic antifungal agents have been developed to improve tolerability while maintaining the efficacy profile of...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics